Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLXBiotechnology
+$0.14 today
- Market cap
- $3.42B
- Beta
- -0.16
- P/E (TTM)
- -11.3
- EPS (TTM)
- -$1.36
Volume 1.51M
Average 1.21M
AMLX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Amylyx Pharmaceuticals, Inc.NASDAQ: AMLX
Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026
Stock-based compensation growth accelerates
Q3 FY2026 stock-based compensation of $10.37M rose 46.6% year over year, ahead of the +11.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 24.7% from the prior quarter. Over 3 fiscal years it compounded at +8.4% a year.
Context
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +46.6% holds above the trailing-twelve-month pace of +11.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 27.65M USD
- Year-over-year change
- -16.3%
- 4-year CAGR
- +72.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.65M | -16.3% |
| FY2024 | 2024-12-31 | 33.04M | -11.1% |
| FY2023 | 2023-12-31 | 37.16M | +71.1% |
| FY2022 | 2022-12-31 | 21.71M | +592.4% |
| FY2021 | 2021-12-31 | 3.14M | — |
Stock-Based Compensation vs competitors
How AMLX compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +11.4% is the 4th highest of 10, against a peer median of -5.5%.
- Over three fiscal years its annual growth of +8.4% compares with a peer median of +6.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $857.38M USD | +71257.3% | +9.4% | — | |
| LTM Sep 2026 | $132.29M USD | +4.4% | +10.1% | 13.8% | |
| LTM Jun 2026 | $69.95M USD | +39.2% | -0.1% | 1941.0% | |
| LTM Mar 2026 | $33.61M USD | -24.5% | +6.3% | 58.0% | |
| LTM Sep 2026 | $31.2M USD | +11.4% | +8.4% | — | |
| LTM Sep 2026 | $26.2M USD | -19.6% | +5.9% | — | |
| LTM Dec 2025 | $10.6M USD | +15.1% | -14.3% | — | |
| LTM Mar 2026 | $9.79M USD | -31.5% | +8.6% | — | |
| LTM Mar 2026 | $7.45M USD | -5.5% | -9.2% | 5559.7% | |
| LTM Dec 2025 | CHF 2.68M CHF | -42.8% | — | 75.0% | |
| Peer median (excluding AMLX) | — | -5.5% | +6.1% | 75.0% | |
Competitors are the stored peer set for AMLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (87.93M) | (198.38M) | 49.27M | (301.74M) | (144.74M) |
| Depreciation & Amortization | 52K | 487K | 1.09M | 904K | 525K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.14M | 21.71M | 37.16M | 33.04M | 27.65M |
| Change in Working Capital | 4.6M | (1.64M) | (65.66M) | (45.83M) | (1.08M) |
| Accounts Receivables | (144K) | (15.31M) | (24.74M) | 39.6M | 383K |
| Inventory | 0 | (9.77M) | (73.13M) | (9.25M) | 0 |
| Accounts Payables | 670K | 1.85M | 15.88M | (19.1M) | 580K |
| Other Working Capital | 4.07M | 21.58M | 16.33M | (57.08M) | (2.05M) |
| Other Non-Cash Items | 5.35M | (2.06M) | (9.94M) | 145.99M | (5.7M) |
| Operating Cash Flow | (74.8M) | (179.87M) | 11.92M | (167.65M) | (123.34M) |
| Capital Expenditures | (353K) | (2.53M) | (1.24M) | (157K) | (138K) |
| Acquisitions (Net) | 0 | 236.46M | 0 | 0 | 0 |
| Purchases of Investments | (49.05M) | (415.87M) | (300.83M) | (231.99M) | (231.82M) |
| Sales of Investments | 3M | 179.41M | 394.12M | 344M | 246M |
| Other Investing Activities | 0 | (236.46M) | 0 | (36.2M) | 0 |
| Investing Cash Flow | (46.41M) | (238.99M) | 92.05M | 75.65M | 14.04M |
| Debt Repayment | 25.9M | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 432.45M | 6.86M | 2.13M | 260.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.39M) | (658K) | (3.32M) | (1.78M) | (3.36M) |
| Financing Cash Flow | 158.51M | 431.79M | 3.54M | 348K | 257.03M |
| Effect of Forex Changes | 13K | (65K) | 160K | (438K) | 1.07M |
| Net Change in Cash | 37.31M | 12.87M | 107.68M | (92.08M) | 148.8M |
| Free Cash Flow | (75.15M) | (182.4M) | 10.68M | (167.8M) | (123.48M) |
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
Intrinsic Alpha fair value
Locked
Current Price
$26.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.